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Background: Brain metastases are a common cause of death in patients with melanoma. The role of adjuvant
whole brain radiotherapy (WBRT) following local treatment of intracranial melanoma metastases is controversial. The
Australian and New Zealand Melanoma Trials Group (ANZMTG) and the Trans-Tasman Radiation Oncology Group
(TROG) are leading the first ever single histology randomised trial investigating this question. The primary endpoint
is distant intracranial failure on magnetic resonance imaging (MRI) within twelve months of randomisation. The first
planned interim analysis was performed twelve months after randomisation of the 100th patient. The analysis was
an opportunity to review completeness of the trial data to date.
Methods: All data received up to the end of twelve months after randomisation of the 100th patient was reviewed.
Results: Review of pathology reports confirmed that all 100 patients had stage IV melanoma and were
appropriately entered into the study. Of the 47 distant intracranial events, 34 occurred in isolation (i.e. only distant
failure was identified), whilst 13 were accompanied by local failure. Data review showed compliance with the
protocol mandated MRI schedule and accuracy of intracranial failure reporting was very high. The Quality of Life
(QoL) component of the study achieved a 91% completion rate. For the neurocognitive function (NCF) assessments,
a high completion rate was maintained throughout the 12 month period. Where assessments were not performed
at expected time points, valid reasons were noted. Radiotherapy quality was high. Of 50 patients who received
WBRT, 32 were reviewed as per protocol design and there was only one major variation out of 308 data points
reviewed (0.3%). There were minimal trial related adverse events (AEs) and no serious adverse events (SAEs). Pre-specified
protocol stopping rules were not met.
Conclusions: The Data Safety Monitoring Committee (DSMC) recommended the trial continue recruitment after
reviewing the unblinded data. The data provision and quality to date indicates that a reliable outcome will be
obtained when the final analysis is performed. Accrual is ongoing with 156 out of 200 patients randomised to
date (26th November 2014).
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Brain metastases (BMs) are common in patients with
metastatic melanoma [1,2] and are the cause of death
in the majority of them [2,3]. Whole brain radiotherapy
(WBRT) is a common adjuvant treatment following
local treatment of BMs with neurosurgery and/or
stereotactic irradiation (SRS). However, there is no specific
level one evidence to support this approach in melanoma.
Proponents believe that WBRT improves palliation by
prolonging intracerebral control [4]. Critics state that
WBRT does not increase survival, may cause neurocogni-
tive problems and may not prevent intracerebral progres-
sion [5,6]. A randomised controlled trial (RCT) is needed
to resolve this controversy in melanoma.
The Australia and New Zealand MelanomaTrials Group
(ANZMTG) and Trans-Tasman Radiation Oncology
Group (TROG) are leading a RCT investigating this
question. This trial is known as the whole brain radiother-
apy in melanoma (WBRTMel) trial. The trial protocol has
previously been published [7]. The primary endpoint is
distant intracranial failure on magnetic resonance imaging
(MRI) within twelve months of randomisation. The total
number of patients required was calculated as being 200,
and a feasibility study was completed and reported [8].
A planned interim analysis performed at twelve months
after randomisation of the 100th patient was triggered
in December 2013. Clinicians remain blinded to the
study results. The interim analysis presented an opportun-
ity to review completeness of the trial data to date and
these data are now presented.
Methods
This is an international, multi-centre, open-label, stratified,
2-arm randomised phase III trial (Figure 1).
The trial has been approved by the Cancer Institute
NSW Clinical Research Ethics Committee #2007C/11/
032 and relevant hospital ethics committees in each par-
ticipating centre. Written informed consent for partici-
pation in the study is obtained from all participants.
The first recruiting centre was opened in December
2008, with the first trial patient randomised in April 2009.
The 100th patient was randomised on 3rd December 2012,Figure 1 Trial Schema.triggering the first planned interim analysis in December
2013. Data collected until that date was reviewed.
Data were reviewed for quality, and the primary end-
point analysed. Histopathology reports (of primary tumour
or metastases) of all 100 patients were independently
reviewed. Data recorded on MRI Case Report Forms
(CRFs) were compared with corresponding MRI reports.
Quality of life (QoL) and neurocognitive function (NCF)
data were reviewed for completeness. Radiotherapy (RT)
quality review was conducted by TROG Quality Assur-
ance (QA) Team. The first 5 patients from each site
randomised to receive whole brain radiotherapy were
reviewed for RT QA. Subsequently, patient reviews
followed a 1 in 5 random sampling basis from each site,
in accordance with the standard TROG QA protocol
for all RT trials. A random sample of 10% of the first
100 patients had all critical data points reviewed for ac-
curacy of entry. Safety data for all 130 patients entered
onto the trial at the time of the analysis were reviewed.
Whilst trial results remain blinded to clinicians and the
Trial Management Committee (TMC), the independent
Data Safety Monitoring Committee (DSMC) were pre-
sented with the unblinded results (i.e. when reviewing the
primary endpoint of the trial, they could ascertain which
arm of the trial each patient had been assigned to). The
DSMC were also provided with the most recent safety
data for all trial patients. The recommendations of the




Demographic information is presented (Table 1). Briefly,
baseline analysis demonstrated even distribution between
the treatment groups (50 patients per arm). The 100
patient cohort included 70% males and 30% females,
aged between 26 and 83 years. Mean ranges of Australian
patients were marginally older than international patients
entering the trial (61 years vs 58 years), but balanced
between treatment arms (WBRT 61 years vs Observation
59 years). Fifty-nine percent of the first 100 patients pre-
sented with a solitary brain metastasis, and the remainder
Table 1 Patient demographics (First 100 patients)







Mean Age (years) Mean 61 (Australian) Mean
58 (International) Range: 26
to 83
Local treatment of BMs
Neurosurgery 62
Stereotactic (Radiosurgery (SRS) 24
Combination of Neurosurgery and SRS 13
None* 1







*One patient died prior to receiving local treatment to their brain metastases.
BM – brain metastases.
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percent of patients presented at baseline with no evidence
of extracranial disease. Demographics reported in this ana-
lysis of the first 100 patients are consistent with the results
of our feasibility study [8].Figure 2 Number of patients presenting with distant intracranial progressi
to the ANZMTG 01.07 WBRTMel Trial.Primary endpoint
The primary endpoint was distant intracranial failure on
MRI within one year. The primary endpoint was reached
in 47 of the first 100 patients: 34 experienced distant
intracranial failure only, while in 13 patients it was
accompanied by local failure (Figure 2).
Protocol compliance
MRI schedule data review revealed high protocol com-
pliance; with 81 of the 100 patients having MRI scans
performed as per protocol (i.e. every 3 months until
distant intracranial progression was reported or until
death). Seven patients did not have one or more of their
scheduled MRI scans within the first 12 months. One
patient had distant failure detected on computed tomog-
raphy (CT) scan. Twelve patients had further MRI scans,
despite confirmation of distant failure. The accuracy of
distant intracranial failure reporting was 100%, but strin-
gent quality assurance checks highlighted some minor
inaccuracies requiring correction despite their lack of
impact on critical end points. Examples of these are
outlined below:
 Only distant failure was reported, when a local
failure was present and should also have been
documented (n = 1).
 Information detailed in the MRI report was found to
be wrong and the CRF was correct (n = 1).
 A local failure was reported twice, as the site had
reported continued growth of a lesion that had
already been recorded as a failure (n = 1).
 For one instance of failure, only one distant lesion
was recorded when two had been identified with the
MRI report (n = 1).on within 365 days of randomisation for the first 100 patients accrued
Table 2 Radiotherapy quality assurance data for 32 patients in the interim analysis
Categories Variables reviewed Acceptable Minor variation Major variation Missing
Schedule 84 82 1 1 0
Dose 110 110 0 0 0
Technique 58 56 2 0 0
Documentation 56 56 0 0 0
Total 308 304(98.7%) 3(1.0%) 1(0.3%) 0
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(Table 2). There was only one major variation among
the 308 data points reviewed (0.3%). This was due to a
patient whose RT delivery time extended beyond 10% of
that expected due to a treatment break for concomitant
illness. Treatment was subsequently completed.
Data quality and safety
Data submitted from all sites were reviewed centrally
for completion. Pathology report review confirmed all
100 patients had evidence of AJCC stage IV melanoma
and were appropriately entered into the study. Comple-
tion of the QoL questionnaires (EORTC QLQC30 and
BN20) has been excellent, with a 91% completion rate.
For those patients participating in the two monthly
NCF assessments (those recruited from Norway were
excluded from this component of the trial as English
fluency to grade 8 level was a prerequisite), compliance
has been high. At baseline 99% of expected assessments
were completed. This completion rate decreased overtime
(Table 3), however stands at 59% at 12 months. When
assessments were not performed at expected time points,
valid reasons were noted (e.g. patient too unwell).
For 10 randomly selected patients, critical data points
within the database were reviewed including the Eastern
Cooperative Oncology Group (ECOG) Performance Sta-
tus scores, the NCF and QoL data, leading to verification
of 4,440 data fields. From this, a minimal data entry
error rate of 0.2% was determined. Safety data review
showed that adverse events (AEs) were minimal, with
only 47 events of grade 3 or 4 occurring (Table 4). No
serious adverse events (SAEs) have been reported to
date. None of the protocol specified stopping rules were
met.
Discussion
The DSMC reviewed the unblinded primary end point
interim analysis data and the corresponding safety data
for this trial. They stated that the trial is progressing in aTable 3 NCF assessment completion
Time point Baseline M
Proportion of expected NCF assessments completed (%) 99 9
For each time point the number of NCF assessments expected to be completed wa
completed. From this the proportion of expected NCF assessments completed weremanner that is safe for patients, the data collected are of
an excellent standard, and no protocol defined stopping
rules have been met. Therefore they recommended the
trial continue to completion. Based on this recommen-
dation, the TMC, blinded to the primary end point ana-
lysis, approved the continuation of the trial. Recruitment
to the trial continues with 156 out of 200 patients cur-
rently randomised (26th November 2014). The primary
end point interim analysis data remains blinded to the
WBRTMel Operations Team, the TMC and all investiga-
tors, clinicians, site staff, and patients.
For the primary endpoint of distant intracranial pro-
gression at 12 months, of the total cohort there were
47 distant intracranial events; 34 occurred in isolation
(i.e. only distant failure was identified), whilst 13 were
accompanied by local failure. This finding indicates that
the trial selection criteria are appropriately identifying
a population at high risk of distant intracranial failure,
and this risk is similar to that reported in other studies.
In a recent retrospective review, Dyer et al. [9] reported
86 of 147 (59%) patients developed distant intracranial
progression at a median of 4.3 months. The addition of
adjuvant WBRT on multivariate analysis being associ-
ated with significantly prolonged intracranial control
(HR 2.24, p = 0.005), especially for those with more
than one BM.
Protocol compliance and high data quality are essential
for ensuring that the trial results are reliable. These results
compare favourably with other practice-changing clinical
trials [10,11]. With regards to the NCF component the
WBRTMel trial will provide a more comprehensive data
set than previous trials [12]. The introduction of hippo-
campal avoidance to the protocol, at centres able to give
WBRT in this manner, will also provide an additional
perspective on WBRT. At the point of final analysis the
NCF of patients who received observation vs WBRT
with hippocampal avoidance vs WBRT without hippo-
campal avoidance will be reviewed. The interim analysis
has allowed an opportunity to recheck and clean theonth 2 Month 4 Month 6 Month 8 Month 10 Month 12
1 78 68 67 52 59
s determined and compared with the number of NCF assessments actually
calculated and is displayed in Table 3.
Table 4 Adverse events*










Disseminated Intravascular Coagulation 0 1
Fatigue 15 2




Muscle weakness 2 0
Nausea 1 0
Pain 3 0
Peripheral motor neuropathy 1 0
Reduced sight 1 0
Renal impairment 1 0
Seizure 2 0
Thromboembolitic event 1 0
Vomiting 3 0
Weight loss 1 0
Total number of AEs at specified grade = 44 3
Total number of AEs = 47
*All AEs have been classified in accordance with CTCAE v 4.0.
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systematic, before the final analysis, due twelve months
after the last patient is randomised. Quality is especially
important in RT trials, some of which may have foundered
because of lack of RT quality control [13].
Conclusion
RCTs are fundamental to improving clinical care via the
use of evidence–based medicine. Based on a planned
interim analysis the WBRTMel trial is safe and with
data of high quality. The trial is on track to answer an
important controversy in melanoma management and
as far as we are aware, remains the first ever reported
single tumour type WBRT trial. The full trial continues,
with 156 patients of the target 200 randomised to date
(26th November 2014).
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